Monashee Investment Management LLC Makes New Investment in Vir Biotechnology, Inc. $VIR

Monashee Investment Management LLC bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 100,000 shares of the company’s stock, valued at approximately $896,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. GSK plc acquired a new position in shares of Vir Biotechnology during the 4th quarter worth $51,562,000. Pictet Asset Management Holding SA lifted its position in shares of Vir Biotechnology by 10,878.9% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,480,828 shares of the company’s stock worth $13,268,000 after buying an additional 1,467,340 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in Vir Biotechnology in the fourth quarter valued at about $8,252,000. State Street Corp boosted its stake in Vir Biotechnology by 18.9% in the fourth quarter. State Street Corp now owns 6,229,555 shares of the company’s stock valued at $37,564,000 after buying an additional 988,262 shares in the last quarter. Finally, Millennium Management LLC grew its position in Vir Biotechnology by 129.2% in the third quarter. Millennium Management LLC now owns 1,396,504 shares of the company’s stock valued at $7,974,000 after acquiring an additional 787,212 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on VIR shares. Wall Street Zen downgraded Vir Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. Morgan Stanley lifted their price target on shares of Vir Biotechnology from $23.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, June 11th. Finally, Leerink Partners lifted their price target on shares of Vir Biotechnology from $20.00 to $21.00 and gave the company an “outperform” rating in a report on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.88.

Vir Biotechnology Stock Down 0.7%

Shares of VIR opened at $9.35 on Thursday. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $11.66. The business has a 50-day simple moving average of $9.34 and a two-hundred day simple moving average of $8.82. The stock has a market cap of $1.58 billion, a PE ratio of -2.99 and a beta of 1.62.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, May 6th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.84). Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 53.31%. The firm had revenue of ($0.03) million during the quarter, compared to the consensus estimate of $55.49 million. During the same quarter in the prior year, the business posted ($0.88) earnings per share. On average, equities research analysts expect that Vir Biotechnology, Inc. will post -1.81 EPS for the current year.

Insider Activity at Vir Biotechnology

In other news, Director Vicki L. Sato sold 22,000 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $10.05, for a total value of $221,100.00. Following the completion of the transaction, the director owned 1,078,391 shares of the company’s stock, valued at $10,837,829.55. This represents a 2.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Janet Napolitano sold 3,200 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.45, for a total transaction of $30,240.00. Following the completion of the transaction, the director owned 21,216 shares of the company’s stock, valued at approximately $200,491.20. This trade represents a 13.11% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,579 shares of company stock valued at $254,922 in the last ninety days. 2.90% of the stock is currently owned by insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.